Emideltide, also called delta sleep-inducing peptide (DSIP), is a nine-amino-acid peptide first isolated from rabbits in 1977 and reported to promote sleep.1 It is not an FDA-approved drug. FDA’s 2026 evaluation found that neither emideltide nor emideltide acetate is a component of an FDA-approved drug, and FDA staff recommended against adding either to the list of substances pharmacies may use in compounding.1 FDA described its human studies, in chronic insomnia, narcolepsy and opioid withdrawal, as small and inconclusive, and found no safety data for the way the nominators proposed to use it.1 Emideltide was reviewed at FDA’s July 2026 advisory meeting but is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,6
Emideltide at a glance
What it is
A peptide of nine amino acids, also called delta sleep-inducing peptide (DSIP), first isolated from rabbit blood and reported to have sleep-inducing properties in animals.1
FDA status
Not FDA-approved. FDA staff recommended in 2026 against adding emideltide or emideltide acetate to the 503A compounding list; FDA had not reported a final decision in the sources reviewed.1
Human evidence
Small studies, some randomized and placebo-controlled, in chronic insomnia, and uncontrolled reports in narcolepsy and opioid withdrawal. FDA found the evidence inconclusive.1
Evidence strength
Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned
What is emideltide?
Emideltide is the nonproprietary name for a peptide of nine amino acids also called delta sleep-inducing peptide (DSIP). FDA’s briefing states that it was first isolated from the blood of rabbits in 1977 and shown to have sleep-inducing properties.1
It exists as a free base and as an acetate salt, which FDA treats as different substances. FDA reports evidence that emideltide-related substances have been used in compounding since at least 2018, and that they have been studied in humans since at least 1981.1
How is emideltide thought to work?
FDA’s briefing states that in animals emideltide has sleep-inducing effects that appear to work through the body’s opioid system: it does not seem to act on opioid receptors directly, but it can stimulate the release of endorphins.1
FDA notes that this action on the opioid system could lead to addiction and that it found no studies of that potential.1
What do human studies show?
FDA evaluated emideltide for chronic insomnia, narcolepsy and opioid withdrawal. For insomnia, it found small studies with mixed results: some reported better sleep, while double-blind, placebo-controlled studies of similar design did not reach the same conclusions.1
FDA describes the insomnia evidence as inconclusive and at best preliminary, citing small samples, weak or missing control groups and unclear clinical meaning.1
The narcolepsy and opioid withdrawal studies were a single case report and small studies without blinding or randomization. In withdrawal studies, headache, nausea and vertigo were common, with cases of low blood pressure, according to FDA.1
The human studies gave emideltide in a different way from the one the nominators proposed, and FDA found no safety or effectiveness data for the proposed way.1
What the evidence base contains
Controlled human trial A randomized, double-blind, placebo-controlled crossover study published in 1981 in six middle-aged adults with chronic insomnia, and later double-blind, placebo-controlled studies that did not reach the same conclusions.1
Small, short, or incompletely reported human study Small open-label studies in opioid withdrawal with no comparison group, and a single-person report in narcolepsy.1
Animal or laboratory research Animal studies, beginning with work in rabbits in 1977, in which emideltide-related substances changed sleep patterns.1
No. FDA’s evaluation, dated May 11, 2026, states that neither emideltide nor emideltide acetate is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for either.1
FDA staff evaluated both forms for the 503A bulks list, the list of substances that pharmacies may use in compounding. They concluded that the balance of criteria weighs against adding either, citing poor characterization, insufficient evidence of effectiveness and a lack of safety data.1
A Federal Register notice and FDA’s meeting page announced that the Pharmacy Compounding Advisory Committee would review peptides including emideltide at its July 23-24, 2026 meeting. The briefing states that FDA will not issue a final determination until the committee’s input has been considered.1,2,3
FDA’s compounding safety-risk page, current as of April 22, 2026, lists emideltide among substances whose nominations were withdrawn, noting possible immune reactions and that FDA lacks enough safety information to know whether it would cause harm.4
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Emideltide is not among them.5,6
Timeline
Emideltide is first isolated from rabbit blood and reported to induce sleep, according to FDA’s briefing.1
FDA’s compounding safety-risk page, as last updated, lists emideltide among withdrawn nominations with safety concerns.4
FDA staff date their evaluation recommending against adding emideltide to the 503A bulks list.1
FDA’s Pharmacy Compounding Advisory Committee begins its two-day meeting reviewing peptides including emideltide.2,3
What is still unknown?
Whether emideltide improves sleep or any other condition: FDA found the evidence inconclusive.1
Its safety with repeated use and in the form the nominators proposed, for which FDA found no data, and its potential for addiction.1
FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 14, 2026.1,2
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Emideltide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Emideltide are the records PeptideScanner has selected and published, not every registration or paper about Emideltide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
Not FDA-approved; under FDA review for pharmacy compounding. FDA staff recommended in 2026 against adding emideltide or emideltide acetate to the 503A compounding list. Emideltide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Two selected small studies examined delta sleep-inducing peptide (DSIP) in chronic insomnia. Their short observation periods and incompletely described formulations limit transfer to other preparations or uses.↗↗
What the reviewed sources report
The two reports differ: one described improved sleep and daytime measures, while the other found weak objective changes and no improvement in subjective sleep quality. These small studies do not establish durable benefit or adequately characterize harms.↗↗
What remains unresolved?
Are the preparations and study populations sufficiently comparable to combine these reports?↗↗
Do larger, longer randomized trials reproduce clinically meaningful sleep improvements?↗↗
Two selected small studies examined delta sleep-inducing peptide (DSIP) in chronic insomnia. Their short observation periods and incompletely described formulations limit transfer to other preparations or uses.12
Bottom line from this bounded source set
The two reports differ: one described improved sleep and daytime measures, while the other found weak objective changes and no improvement in subjective sleep quality. These small studies do not establish durable benefit or adequately characterize harms.12
Reviewed study record
Chronic insomnia: matched-pairs study
Design
A blinded placebo-controlled parallel-group study used matched pairs and five consecutive laboratory nights.1
Population
Sixteen patients with chronic insomnia participated.1
Outcomes reported
Sleep efficiency and sleep latency differed from placebo, but the authors described the effects as weak and partly attributable to changes in the placebo group. Subjective sleep quality did not improve.1
Limitations
The abstract does not describe random allocation or detailed adverse events. A short, small study cannot establish sustained benefit or uncommon harms.1
Reviewed study record
Chronic insomnia: sleep and daytime performance
Design
A blinded placebo-controlled study observed sleep and daytime performance over seven successive treatment nights.2
Population
Fourteen middle-aged participants with chronic insomnia were studied.2
Outcomes reported
The authors reported improved sleep, alertness and daytime performance, with sleep effects maintained on the first post-treatment night.2
Limitations
The abstract does not clearly describe allocation, the full comparator sequence or adverse events. The findings do not establish longer-term efficacy or safety.2
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1159/000118919. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1159/000116143. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Different proposed uses have different evidence gaps
FDA’s July 2026 briefing assessed chronic insomnia, narcolepsy and opioid withdrawal separately. Small heterogeneous sleep studies and a single-person narcolepsy report did not establish durable clinical benefit. FDA PDF pp. 32, 33, 34, 36 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
Withdrawal reports lacked robust controls
FDA described small open-label studies with no comparison group, inconsistent outcome methods and limited completion. Apparent short-term changes do not establish an effective maintenance treatment. FDA PDF pp. 38, 39 ↗
The route mismatch is material
The clinical reports discussed intravenous administration, while the nomination proposed subcutaneous use. FDA reported no safety data for that proposed route and insufficient characterization of chronic intermittent use. FDA PDF pp. 53, 56 ↗
A briefing proposal is not a final decision
FDA staff proposed against adding the nominated substances to the 503A bulks list, citing quality, effectiveness and safety gaps. The document explicitly precedes the final agency determination. FDA PDF pp. 1, 53, 56 ↗
What remains to be checked
Check subsequent advisory records and any final FDA action separately from the staff briefing.
Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Primary human administration reports for the specified molecule; other peptides, preclinical experiments and secondary reviews are separate.
463 retrieved · 2 included · 0 excluded · 461 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"delta sleep-inducing peptide"[Title/Abstract] OR "DSIP"[Title/Abstract] OR "emideltide"[Title/Abstract]
Regulator and trial-registry searches and non-indexed reports require separate reconciliation.
Full-text appraisal, study-family linkage and citation follow-up remain open.
Showing 25 of 463 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 1299794 — include: Selected human report; abstract and record metadata reviewed. Study families: DSIP-1992-matched-pairs-linkage-unresolved.
PubMed 3622582 — include: Selected human report; abstract and record metadata reviewed. Study families: DSIP-1987-insomnia-linkage-unresolved.
PubMed 41490200 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 39798527 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 39444618 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 38854576 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 37884638 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 36042828 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 34500605 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 33918965 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 33019716 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 32456912 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 30107169 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 28549673 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 28462721 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 26931331 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 26902351 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 29124188 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 25805003 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 26470489 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 25581971 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 25257425 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 25063142 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 24607477 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 25898718 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Emideltide?
Not FDA-approved; under FDA review for pharmacy compounding. FDA staff recommended in 2026 against adding emideltide or emideltide acetate to the 503A compounding list. Emideltide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗
The cited status sources were checked through July 29, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
PubMed bibliography
Publication composition
17 of 42 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 17Research Support, U.S. Gov't, Non-P.H.S. 8Research Support, Non-U.S. Gov't 5Comparative Study 3Research Support, U.S. Gov't, P.H.S. 2Review 1
Bibliography fields unavailable here for 25 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
44
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 44 dated records
We added a plain-language reader guide with cited answers, re-checked FDA’s emideltide briefing and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include emideltide.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.
Selected records span November 14, 2003 to July 24, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.↗
PubMed lists PMID 11321250 in Folia biologica as Journal Article, with publication-date metadata of 2001 (year precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 6132770 in Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology as Comparative Study, Journal Article, with publication-date metadata of 1983 (year precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 3367267 in Journal of pineal research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1988 (year precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 3286557 in The International journal of neuroscience as Journal Article, Review, with publication-date metadata of 1988-02 (month precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 1800948 in Peptides as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1991 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 6897115 in Peptides as Journal Article, with publication-date metadata of 1982 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 318193 in Brain research bulletin as Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 1978 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 3768731 in Brain research bulletin as Comparative Study, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 1986-08 (month precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 6895711 in Brain research bulletin as Comparative Study, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 1981-12 (month precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 6549071 in Pharmacology, biochemistry, and behavior as Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 1984-11 (month precision). PeptideScanner associated the retained record with the identity slug emideltide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗